Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Inclusion Criteria: * Diagnosis of metastatic colorectal, neuroendocrine, cholangiocarcinoma, melanoma, or breast malignancy with liver dominant disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria. * The cancer is unresectable. * All patients must be off all chemotherapeutic regimens for 30 days prior to and 30 days after TheraSphere treatment. Concurrent therapy with octreotide is permitted, when appropriate. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Age 18 years or older. * Able to understand informed consent. Exclusion Criteria: * Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either: * single TheraSphere administration; or * cumulative delivery of radiation to the lungs greater than 50 Gy over multiple treatments. * Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition. * Previous radiation therapy to the lungs and/or to the upper abdomen * Pregnancy * Symptomatic lung disease. * Significant extrahepatic disease representing an imminent life-threatening outcome. * Active uncontrolled infection * Any pre-treatment laboratory findings within 30 days of treatment demonstrating: * Aspartate or alanine aminotransferase level greater than 5 times upper normal limit. * Serum bilirubin greater than 2 mg/dl * Infiltrative tumor on imaging * Tumor volume greater than 70% of liver volume * Tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dL